Estradiol/drospirenone
Source: Wikipedia, the free encyclopedia.
Combination drug
Antimineralocorticoid; Antiandrogen | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
CAS Number |
Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a
postmenopausal women.[1][2][3] It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet.[1] The medication was approved in the United States in 2005.[1] It is marketed widely throughout the world.[4]
See also
- Estetrol/drospirenone
- Ethinylestradiol/drospirenone
- Ethinylestradiol/drospirenone/levomefolic acid
- Ethinylestradiol/drospirenone/prasterone
- List of combined sex-hormonal preparations § Estrogens and progestogens
References
- ^ a b c "ANGELIQ (drospirenone and estradiol) Prescribing Information" (PDF). Bayer HealthCare Pharmaceuticals Inc. U.S. Food and Drug Administration. February 2012.
- ^ "Estradiol/Drospirenone - Bayer HealthCare Pharmaceuticals". AdisInsight.
- S2CID 7305124.
- ^ "Drospirenone and Estradiol: Uses, Side Effects & Warnings".
External links
|
| |||
---|---|---|---|---|
SPRMs Tooltip Selective progesterone receptor modulators | ||||
PRTooltip Progesterone receptor antagonists |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Progesterone receptor modulators
- Androgens and antiandrogens
- Estrogens and antiestrogens
- List of progestogens
| |
---|---|
Mineralocorticoids |
|
Antimineralocorticoids | |
Synthesis modifiers | |
|
|
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antiandrogens |
| ||||||||||||
|